Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes

Plain-language summary

This study looks at genetic screening and molecular diagnosis to guide individualized care for monogenic diabetes. It enrolls people who developed diabetes before age 25, or who were diagnosed before age 35 with a family history of early diabetes, with a body mass index under 28 at diagnosis and negative diabetes autoantibodies. It is a non-phase study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Tianjin Medical University General Hospital

Intervention

Genetic Screening for Monogenic Diabetes

Start date

8/1/2022

Estimated completion

7/31/2027

Countries

China

Related genes

Locations

• Tianjin, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Diabetes patients who developed before 25 years old; Or they were diagnosed with diabetes before the age of 35, and two or more immediate relatives were diagnosed with diabetes before the age of 45;
2. Body mass index (BMI) at diagnosis \< 28 kg/m2;
3. Anti glutamic acid decarboxylase antibody (GAD Ab), anti islet cell antibody (ICA Ab), and anti insulin autoantibody (IAA Ab) were all negative;

Exclusion Criteria:

1. Secondary diabetes patients with other endocrine diseases, such as hyperthyroidism or hypothyroidism, hyperparathyroidism or hypothyroidism, acromegaly, Cushing's syndrome, autoimmune multiple endocrine diseases, etc.;
2. Systemic use of corticosteroids, immunosuppressants, and other drugs within the past 6 months;
3. Patients with malignant tumors.